The medical technology firm reported a Q1 GAAP loss alongside $356,000 in cash and $2.4 million in digital assets.
Endra Life Sciences reported a first-quarter GAAP loss of $1.09 per share, reflecting ongoing operational costs. The company’s financial position includes $356,000 in cash and cash equivalents as of March 31, 2026.
The firm also holds approximately $2.4 million in its Digital Asset Treasury, part of its broader capital management strategy. No prior quarterly comparisons or consensus estimates were provided in the release.
Market reaction was not disclosed in the announcement.